Article Text

Download PDFPDF

PS3:52 Incidence and clinical features of neuropsychiatric lupus in korea: a prospective single-centre study
  1. GY Ahn1,
  2. D Kim1,
  3. SY Won2,
  4. ST Song3,
  5. HJ Jung4,
  6. IW Son5,
  7. S Lee6,
  8. YB Joo7 and
  9. SC Bae1
  1. 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
  2. 2Clinical Research Centre for Rheumatoid Arthritis, Seoul, South Korea
  3. 3Department of Rheumatology, Cheongju St. Mary’s Hospital, Cheongju, South Korea
  4. 4Department of Rheumatology, Keimyung University Dongsan Medical Centre, Daegu, South Korea
  5. 5Department of Rheumatology, Chung Hospital, Seoul, South Korea
  6. 6Rheuma Lee’s Hospital, Busan, South Korea
  7. 7Department of Rheumatology, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea


Objective To identify the incidence, risk factors and prognosis for neuropsychiatric lupus (NPSLE) in Korea.

Methods 1121 patients with SLE from Hanyang BAE lupus cohort were enrolled and followed from 1998 to 2015. NPSLE was defined using the ACR case definitions and Ainiala Criteria. Demographics and clinical information including ACR Classification criteria for SLE, autoantibodies, SLE Disease Activity Index, the SLICC/ACR damage index (DI) were collected at baseline and then annually. Symptoms of NPSLE were collected from patient interview and medical records. Mortality data were derived by linking with data from the Korean National Statistics Office (KNSO). Multivariable logistic regression and cox regression test were performed to assess the risk factor of NPSLE and predictors of mortality.

Results Of 1121 SLE patients, 429 (38.2%) patients had NPSLE events according to ACR definitions and 216 (19.3%) by Ainiala criteria. In multivariable logistic regression analysis, year of education [Odds ratio (OR) 0.92, 95% confidence interval (CI) 0.87 to 0.96, p<0.01] and elevated anti-dsDNA antibodies (OR 0.52, CI: 0.37 to 0.76, p<0.01) decreased the risk of NPSLE. In multivariable cox regression analysis, SLEDAI without NP manifestations at enrollment increased the risk of mortality (OR 1.18, CI: 1.08 to 1.25, p<0.01) in NPSLE patients.

Conclusion The 38.2% and 19.3% of SLE patients had NPSLE according to ACR and Ainiala definition of NPSLE. Year of education and elevated anti-dsDNA antibodies decreased the risk of occurrence of NPSLE. SLEDAI without NP manifestations at enrollment increased the risk of mortality in NPSLE patients.

Abstract PS3:52 Table 1

Prevalence of ACR/Ainiala NPSLE manifestations

Abstract PS3:52 Table 2

Risk factors for the occurrence of NPSLE manifestations (n=908)

  • Systematic Lupus Erythamatosus
  • Neuropsychiatric
  • prevalence

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.